NCT-58
NCT-58 is a potent inhibitor of C-terminal HSP90. NCT-58 does not induce the heat shock response (HSR) due to its targeting of the C-terminal region and elicits anti-tumor activity via the simultaneous downregulation of HER family members as well as inhibition of Akt phosphorylation. NCT-58 kills Trastuzumab-resistant breast cancer stem-like cells. NCT-58 induces apoptosis in HER2-positive breast cancer cells[1].
Product Specifications
CAS Number
[2411429-33-7]
UNSPSC
12352005
Target
Apoptosis; HSP
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/nct-58.html
Purity
99.63
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C(C1=CC=C2OC(C)(C)C=CC2=C1OC)NC3=CC=C(C(OC)=C3)OCCC4NCCCC4
Molecular Formula
C27H34N2O5
Molecular Weight
466.57
References & Citations
[1]Park S, et al. The C-terminal HSP90 inhibitor NCT-58 kills trastuzumab-resistant breast cancer stem-like cells. Cell Death Discov. 2021;7 (1) :354.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
HSP90
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
![Mouse Monoclonal Desmoglein-3 Antibody (DSG3/2796) [PerCP]](https://cdn.genprice.uk/genprice/uk/genprice2.webp)
SPG7, ID (SPG7, CAR, CMAR, PGN, Paraplegin, Spastic paraplegia 7 protein) (AP) discontinued
LDLR (Low-density Lipoprotein Receptor, LDL Receptor) (MaxLight 750)
LDLR (Low-density Lipoprotein Receptor, LDL Receptor) (MaxLight 750)